Restricted accessResearch articleFirst published online 2014-08
Genomic Analysis and Differential Expression of HMG and S100A Family in Human Arthritis: Upregulated Expression of Chemokines,IL-8 and Nitric Oxide by HMGB1
We applied global gene expression arrays, quantitative real-time PCR, immunostaining, and functional assays to untangle the role of High Mobility Groups proteins (HMGs) in human osteoarthritis (OA)-affected cartilage. Bioinformatics analysis showed increased mRNA expression of Damage-Associated Molecular Patterns (DAMPs): HMGA, HMGB, HMGN, SRY, LEF1, HMGB1, MMPs, and HMG/RAGE-interacting molecules (spondins and S100A4, S100A10, and S100A11) in human OA-affected cartilage as compared with normal cartilage. HMGB2 was down-regulated in human OA-affected cartilage. Immunohistological staining identified HMGB1 in chondrocytes in the superficial cartilage. Cells of the deep cartilage and subchondral bone showed increased expression of HMGB1 in OA-affected cartilage. HMGB1 was expressed in the nucleus, cytosol, and extracellular milieu of chondrocytes in cartilage. Furthermore, HMGB1 was spontaneously released from human OA-affected cartilage in ex vivo conditions. The effects of recombinant HMGB1 was tested on human cartilage and chondrocytes in vitro. HMGB1 stimulated mRNA of 2 NFκB gene enhancers (NFκB1 and NFκB2), 16 CC and CXC chemokines (IL-8, CCL2, CCL20, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L1, CCL4L2, CCL5, CCL8, CXCL1, CXCL10, CXCL2, CXCL3, and CXCL6) by ≥10-fold. Furthermore, HMGB1 and IL-1β and/or tumor necrosis factor α (but not HMGI/Y) also significantly induced inducible nitric oxide synthase, NO, and interleukin (IL)-8 production in human cartilage and chondrocytes. The recombinant HMGB1 utilized in this study shows properties that are similar to disulfide-HMGB1. The differential, stage and/or tissue-specific expression of HMGB1, HMGB2, and S100A in cartilage was associated with regions of pathology and/or cartilage homeostasis in human OA-affected cartilage. Noteworthy similarities in the expression of mouse and human HMGB1 and HMGB2 were conserved in normal and arthritis-affected cartilage. The multifunctional forms of HMGB1 and S100A could perpetuate damage-induced cartilage inflammation in late-stage OA-affected joints similar to sterile inflammation. The paracrine effects of HMGB1 can induce chemokines and NO that are perceived to change cartilage homeostasis in human OA-affected cartilage.
Get full access to this article
View all access options for this article.
References
1.
AbramsonS.B., AminA.R., ClancyR.M., and AtturM. (2001a). The role of nitric oxide in tissue destruction. Best practice & research. Clin Rheumatol, 15, 831–845.
2.
AbramsonS.B., AtturM., AminA.R., and ClancyR. (2001b). Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep, 3, 535–541.
3.
AdjayeJ., HuntrissJ., HerwigR., BenKahlaA., BrinkT.C., WierlingC., HultschigC., GrothD., YaspoM.L., PictonH.M., GosdenR.G., and LehrachH. (2005). Primary differentiation in the human blastocyst: comparative molecular portraits of inner cell mass and trophectoderm cells. Stem Cells, 23, 1514–1525.
4.
AlaaeddineN., OleeT., HashimotoS., Creighton-AchermannL., and LotzM. (2001). Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum, 44, 1633–1643.
5.
AllenS.J., CrownS.E., and HandelT.M. (2007). Chemokine: receptor structure, interactions, and antagonism. Ann Rev Immunol, 25, 787–820.
6.
AminA.R., and AbramsonS.B. (1998). The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol, 10, 263–268.
7.
AminA.R., AtturM., and AbramsonS.B. (1999). Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Curr Opin Rheumatol, 11, 202–209.
8.
AminA.R., AtturM., PatelR.N., ThakkerG.D., MarshallP.J., RediskeJ., StuchinS.A., PatelI.R., and AbramsonS.B. (1997). Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest, 99, 1231–1237.
9.
AminA.R., AtturM.G., ThakkerG.D., PatelP.D., VyasP.R., PatelR.N., PatelI.R., and AbramsonS.B. (1996). A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A, 93, 14014–14019.
10.
AminA.R., ThompsonS., and AminS. (2007). Future of Genomics in Diagnosis of Human Arthritis: the hype, hope and metamorphosis for tomorrow. Future Med, 2, 4–7.
11.
AnderssonU., and HarrisE. (2004). HMGB1 is a potent trigger of arthritis. J Intern Med, 255, 344–350.
12.
AtturM.G., DaveM., AkamatsuM., KatohM., and AminA.R. (2002a). Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine. Osteoarthritis Cartilage, 10, 1–4.
13.
AtturM.G., DaveM., CipollettaC., KangP., GoldringM.B., PatelI.R., AbramsonS.B., and AminA.R. (2000). Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem, 275, 40307–40315.
14.
AtturM.G., DaveM.N., LeungM.Y., CipollettaC., MeseckM., WooS.L., and AminA.R. (2002b). Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol, 168, 2001–2010.
15.
AtturM.G., DaveM.N., StuchinS., KowalskiA.J., SteinerG., AbramsonS.B., DenhardtD.T., and AminA.R. (2001). Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum, 44, 578–584.
16.
AtturM.G., DaveM.N., TsunoyamaK., AkamatsuM., KoboriM., MikiJ., AbramsonS.B., KatohM., and AminA.R. (2002c). “A system biology” approach to bioinformatics and functional genomics in complex human diseases: arthritis. Curr Issues Mol Biol, 4, 129–146.
17.
AtturM.G., PalmerG.D., Al-MussawirH.E., DaveM., TeixeiraC.C., RifkinD.B., AppletonC.T., BeierF., and AbramsonS.B. (2009). F-spondin, a neuroregulatory protein, is up-regulated in osteoarthritis and regulates cartilage metabolism via TGF-beta activation. FASEB J, 23, 79–89.
18.
AtturM.G., PatelI.R., PatelR.N., AbramsonS.B., and AminA.R. (1998). Autocrine production of IL-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Phys, 110, 65–72.
19.
BianL. (2011). The role of S100A4 protein as a regulator of inflammation and bone metabolism in experimental arthritis. PhD thesis. Dept of Rheumatology and Inflammtion Research. The Sahlgtrenska Academy. University of Gothenburg. Gothenburg. Sweden.
20.
BorziR.M., MazzettiI., MagagnoliG., PaolettiS., UguccioniM., GattiR., OrlandiniG., CattiniL., and FacchiniA. (2002). Growth-related oncogene alpha induction of apoptosis in osteoarthritis chondrocytes. Arthritis Rheum, 46, 3201–3211.
21.
BorziR.M., MazzettiI., MarcuK.B., and FacchiniA. (2004). Chemokines in cartilage degradation. Clin Orthop Relat Res, 427, S53–S61.
22.
BustinM. (2010). High mobility group proteins. Biochim Biophys Acta, 1799, 1–2.
23.
CarlevaroM.F., CermelliS., CanceddaR., and CanceddaF. (2000). Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. J Cell Sci, 113, 59–69.
24.
CecilD.L., JohnsonK., RediskeJ., LotzM., SchmidtA.M., and TerkeltaubR. (2005). Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol, 175, 8296–8302.
25.
CecilD.L, and TerkeltaubR. (2008). Transamidation by transglutaminase 2 transforms S100A calgranulin into a procatabolic cytokine for chondrocytes. J Immunol, 180, 8378–8385.
26.
ChenG.Y., and NuñezG. (2010). Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol, 10, 826–837.
27.
CristinoS., PiacentiniA., ManferdiniC., CodeluppiK., GrassiF., FacchiniA., and LisignoliG. (2008). Expression of CXC chemokines and their receptors is modulated during chondrogenic differentiation of human mesenchymal stem cells grown in three-dimensional scaffold: evidence in native cartilage. Tissue Eng Part A, 14, 97–105.
28.
CuddapahS., SchonesD.E., CuiK., RohT.Y., BarskiA., WeiG., RochmanM., BustinM., and ZhaoK. (2011). Genomic profiling of HMGN1 reveals an association with chromatin at regulatory regions. Mol Cell Biol, 31, 700–709.
29.
DaveM., and AminA.R. (2013). Yin-Yang regulation of prostaglandins and nitric oxide by PGD2 in human arthritis: reversal by celecoxib. Immunol Lett, 152, 47–54.
30.
De CeuninckF., MarcheteauE., BergerS., CaliezA., DumontV., RaesM., AnractP., LeclercG., BoutinJ.A., and FerryG. (2005). Assessment of some tools for the characterization of the human osteoarthritic cartilage proteome. J Biomol Tech, 16, 256–265.
31.
De JongeH.J., FehrmannR.S., de BontE.S., HofstraR.M., GerbensF., KampsW.A., de VriesE.G., van der ZeeA.G., te MeermanG.J., and ter ElstA., (2007). Evidence based selection of housekeeping genes. PloS One, 2, e898.
EllmanM.B., YanD., AhmadiniaK., ChenD., AnH.S, and ImH.J., (2013). Fibroblast growth factor control of cartilage homeostasis. J Cell Biochem, 114, 735–742.
34.
EndresM., AndreasK., KalwitzG., FreymannU., NeumannK., RingeJ., SittingerM., HauplT., and KapsC., (2010). Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells. Osteoarthritis Cartilage, 18, 1458–1466.
35.
ErlandssonM.C., SvenssonM.D., JonssonI.M., BianL., AmbartsumianN., AnderssonS., PengZ., VaaraniemiJ., OhlssonC., AnderssonK.M., and BokarewaM.I. (2013). Expression of metastasin S100A4 is essential for bone resorption and regulates osteoclast function. Biochim Biophys Acta, 1833, 2653–2663.
36.
García-ArnandisI., GuillénM.I., GomarF., PelletierJ.P., Martel-PelletierJ.M., and AlcarazM.J. (2001). High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1β in osteoarthritic synoviocytes. Arthritis Rheum, 44, 1555–1567.
37.
GeG., SeoN.S., LiangX., HopkinsD.R., HöökM., and GreenspanD.S. (2004). Bone morphogenetic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. J Biol Chem, 279, 41626–41633.
38.
GoldsteinR.S., BruchfeldA., YangL., QureshiA.R., Gallowitsch-PuertaM., PatelN.B., HustonB.J., ChavanS., Rosas-BallinaM., GregersenP.K., CzuraC.J., SloanR.P., SamaA.E., and TraceyK.J. (2007). Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med, 13, 210–215.
39.
GrassiF., PiacentiniA., CristinoS., ToneguzziS., CavalloC., FacchiniA., and LisignoliG. (2003). Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12. Histochem Cell Biol, 120, 391–400.
40.
Hans-PeterG., ThiennuH., RyanA.M., KowalskiJ., WerbZ., and FerraraN. (1999). EGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med, 5, 623–628.
41.
HaringmanJ.J., LudikhuizeJ., and TakP.P. (2004). Chemokines in joint disease: the key to inflammation?. Ann Rheum Dis, 63, 1186–1194.
42.
HarrisH.E., AnderssonU., and PisetskyD.S. (2012). HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol, 8, 195–202.
43.
HaseebA., and HaqqiT.M. (2013). Immunopathogenesis of osteoarthritis. Clin Immunol, 146, 185–196.
44.
HaydenM.S, and GhoshS. (2012). NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev, 26, 203–234.
45.
HeinolaT., KouriV.P., ClarijsP., CiferskaH., SukuraA, SaloJ., and KonttinenYT.2010. High mobility group box-1 (HMGB-1) in osteoarthritic cartilage. Clin Exp Rheumatol, 28, 511–518.
46.
IkedaT., KawaguchiH., KamekuraS., OgataN., MoriY., NakamuraK., IkegawaS., and ChungU. (2005). Distinct roles of Sox5, Sox6, and Sox9 in different stages of chondrogenic differentiation. Bone Miner Metab, 23, 237–240.
47.
JankoC., FilipovićM., MunozL.E., SchornC., SchettG., Ivanović-BurmazovićI., and HerrmannM. (2014). Redox Modulation of HMGB1-Related Signaling. Antioxid Redox Signal, 20, 1075–1085.
48.
JinD., WuY., ZhaoL., GuoJ., ZhangK., and ChenZ. (2012). Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia. Exp Ther Med, 4, 1124–1126.
49.
JohnsonK.A., van EttenD., NandaN., GrahamR.M., and TerkeltaubR.A. (2003). Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy. J Biol Chem, 278, 18824–18832.
50.
KangR., TangD., SchapiroN.E., LouxT., LiveseyK.M., BilliarT.R., WangH., Van HoutenB., LotzeM.T., and ZehH.J. (2013). The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene, 33, 567–577.
51.
KewR.R., PenzoM., HabielD.M., and MarcuK.B. (2012). The IKKα-dependent NF-κB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1. J Immunol, 188, 2380–2386.
52.
KimH.A., LeeY.J., SeongS.C., ChoeK.W., and SongW. (2000). Apoptotic chondrocyte death in human osteoarthritis. J Rheumatol, 27, 455–462.
KokkolaR., SundbergE., UlfgrenA.K., PalmbladK., LiJ., WangH., UlloaL., YangH., YanX.J., FurieR., ChiorazziN., TraceyK.J., AnderssonU., and HarrisH.E. (2002). High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. Arthritis Rheum, 46, 2598–2603.
55.
Kyostio-MooreS., NambiarB., HuttoE., EwingP.J., PirainoS., BertheletteP., SookdeoC., MatthewsG., and ArmentanoD. (2011). STR/ort mice, a model for spontaneous osteoarthritis, exhibit elevated levels of both local and systemic inflammatory markers. Comp Med, 61, 346–355.
56.
KyriakidesT.R., JessicaW.Y., and BornsteinP. (1999). Wound Healing in Mice with a disruption of the Thrombospondin 2 Gene. J Invest Dermatol, 113, 782–787.
57.
LamoreS.D., CabelloC.M., and WondrakG.T. (2010). HMGB1-directed drug discovery targeting cutaneous inflammatory dysregulation. Curr Drug Metab, 11, 250–265.
58.
LiG., LiangX., and LotzeM.T. (2013). HMGB1: the central cytokine for all lymphoid cells. Front Immunol, 4, 68–75.
LisignoliG., ManferdiniC., CodeluppiK., PiacentiniA., GrassiF., CattiniL., FilardoG., and FacchiniA. (2009). CCL20/CCR6 chemokine/receptor expression in bone tissue from osteoarthritis and rheumatoid arthritis patients: different response of osteoblasts in the two groups. J Cell Physiol, 221, 154–160.
61.
LisignoliG., PiacentiniA., CristinoS., GrassiF., CavalloC., CattiniL., TonnarelliB., ManferdiniC., and FacchiniA. (2007). CCL20 chemokine induces both osteoblast proliferation and osteoclast differentiation: Increased levels of CCL20 are expressed in subchondral bone tissue of rheumatoid arthritis patients. J Cell Physiol, 210, 798–806.
62.
Liu-BryanR., and TerkeltaubR. (2010). Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. Arthritis Rheum, 62, 2004–2012.
LotzM., TerkeltaubR., and VilligerP.M. (1992). Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes. J Immunol, 148, 466–473.
65.
MerzD., LiuR., JohnsonK., and TerkeltaubR. (2003). IL-8/CXCL8 and growth-related oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol, 171, 4406–4415.
66.
MullerS., ScaffidiP., DegryseB., BonaldiT., RonfaniL., AgrestiA., BeltrameM., and BianchiM.E. (2001). New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J, 20, 4337–4340.
67.
MurataM., YudohK., and MasukoK. (2008). The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis?. Osteoarthritis Cartilage, 16, 279–286.
PalmbladK., SundbergE., DiezM., SoderlingR., AvebergerA.C., AnderssonU., and HarrisH.E. (2007). Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. Arthritis Res Ther, 9, R35.
70.
PalmerG.D., PitonA.H., ThantL.M., OliveiraS.M., D'AngeloM., AtturM.G., AbramsonS.B., and TeixeiraC.C. (2010). F-spondin (Spondin 1) regulates chondrocyte terminal differentiation and endochondral bone formation. J Orthop Res, 28, 1323–1329.
71.
PatelI.R., AtturM.G., PatelR.N., StuchinS.A., AbagyanR.A., AbramsonS.B., and AminA.R. (1998). TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha. J Immunol, 160, 4570–4579.
72.
PelletierJ.P., Martel-PelletierJ., and AbramsonS.B. (2001). Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum, 44, 1237–1247.
73.
Perez-LlamasC., and Lopez-BigasN. (2011). Gitools: analysis and visualisation of genomic data using interactive heat-maps. PloS One, 6, e19541.
74.
PritzkerK.P., GayS., JimenezS.A., OstergaardK., PelletierJ.P., RevellP.A., SalterD., and van den BergW.B. (2006). Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage, 14, 13–29.
75.
PulleritsR., JonssonI.M., KolliasG., and TarkowskiA. (2008). Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumor necrosis factor signaling. Arthritis Res Ther, 10, R72.
76.
PulleritsR., JonssonI.M., VerdrenghM., BokarewaM., AnderssonU., Erlandsson-HarrisH., and TarkowskiA. (2003). High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum, 48, 1693–1700.
77.
PulsatelliL., AddimandaO., BrusiV., PavloskaB., and MeliconiR. (2013). New findings in osteoarthritis pathogenesis: therapeutic implications. Ther Adv Chronic Dis, 4, 23–43.
78.
PulsatelliL., DolzaniP., PiacentiniA., SilvestriT., RuggeriR., GualtieriG., MeliconiR., and FacchiniA. (1999). Chemokine production by human chondrocytes. J Rheumatol, 26, 1992–2001.
79.
RaoJ., ElliottM.R., LeitingerN., JensenR.V., GoldbergJ.B., and AminA.R. (2011). RahU: an inducible and functionally pleiotropic protein in Pseudomonas aeruginosa modulates innate immunity and inflammation in host cells. Cell Immunol, 270, 103–113.
80.
SchiraldiM., RaucciA., MunozL.M., LivotiE., CelonaB., VenereauE., ApuzzoT., De MarchisF., PedottiM., BachiA., ThelenM., VaraniL., MelladoM., ProudfootA., BianchiM.E., and UguccioniM. (2012). HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med, 209, 551–563.
SimsG.P., RoweD.C., RietdijkS.T., HerbstR., and CoyleA.J. (2010). HMGB1 and RAGE in inflammation and cancer. Ann Rev Immunol, 28, 367–388.
83.
SmythG.K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 3, Article3.
84.
SongC., ZhouX., DongQ., FanR., WuG., JiB., MengQ., and ZhengM. (2012). Regulation of inflammatory response in human chondrocytes by lentiviral mediated RNA interference against S100A10. Inflamm Res, 61, 1219–1227.
85.
SparveroL.J., Asafu-AdjeiD., KangR., TangD., AminN., ImJ., RutledgeR., LinB., AmoscatoA.A., ZehH.J., and LotzeM.T. (2009). RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med, 7, 17.
86.
TanakaK., MatsumotoE., HigashimakiY., KatagiriT., SugimotoT., SeinoS., and KajiH. (2012). Role of osteoglycin in the linkage between muscle and bone. J Biol Chem, 287, 11616–11628.
87.
TangD., BilliarT.R., and LotzeM.T. (2012). A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med, 18, 1360–1362.
88.
TaniguchiN., CaramesB., HsuE., CherquiS., KawakamiY., and LotzM. (2011). Expression patterns and function of chromatin protein HMGB2 during mesenchymal stem cell differentiation. J Biol Chem, 286, 41489–41498.
89.
TaniguchiN., CaramesB., RonfaniL., UlmerU., KomiyaS., BianchiM.E., and LotzM. (2009). Aging-related loss of the chromatin protein HMGB2 in articular cartilage is linked to reduced cellularity and osteoarthritis. Proc Natl Acad Sci U S A, 106, 1181–1186.
90.
TaniguchiN., YoshidaK., ItoT., TsudaM., MishimaY., FurumatsuT., RonfaniL., AbeyamaK., KawaharaK., KomiyaS., MaruyamaI., LotzM., BianchiM.E., and AsaharaH. (2007). Stage-specific secretion of HMGB1 in cartilage regulates endochondral ossification. Mol Cell Biol, 27, 5650–5663.
TaylorD.K., MeganckJ.A., TerkhornS., RajaniR., NaikA., O'KeefeR.J., GoldsteinS.A., and HankensonK.D. (2009). Thrombospondin-2 influences the proportion of cartilage and bone during fracture healing. J Bone Miner Res, 24, 1043–1054.
93.
UrbonaviciuteV., MeisterS., FürnrohrB.G., FreyB., GückelE., SchettG., HerrmannM., and VollR.E. (2009). Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity, 42, 305–307.
94.
Van LentP.L., GreversL.C., BlomA.B., ArntzO.J., van de LooF.A., van der KraanP., Abdollahi-RoodsazS., SrikrishnaG., FreezeH., SloetjesA., NackenW., VoglT., RothJ, and van den BergWB. (2008). Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. Arthritis Rheum, 58, 3776–3787.
95.
VelegrakiM., KoutalaH., TsatsanisC., and PapadakiH.A. (2012). Increased levels of the high mobility group box 1 protein sustain the inflammatory bone marrow microenvironment in patients with chronic idiopathic neutropenia via activation of toll-like receptor 4. J Clin Immunol, 32, 312–322.
96.
VenereauE., CasalgrandiM., SchiraldiM., AntoineD.J., CattaneoA., De MarchisF., LiuJ., AntonelliA., PretiA., RaeliL., ShamsS.S., YangH., VaraniL., AnderssonU., TraceyK.J., BachiA., UguccioniM., and BianchiM.E. (2012). Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med, 209, 1519–1528.
97.
WahamaaH., VallerskogT., QinS., LunderiusC., LaRosaG., AnderssonU., and HarrisH.E. (2007). HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J Leukoc Biol, 81, 129–136.
98.
WangG., YanQ., WoodsA., AubreyL.A., FengQ., and BeierF. (2011). Inducible nitric oxide synthase-nitric oxide signaling mediates the mitogenic activity of Rac1 during endochondral bone growth. J Cell Sci, 124, 3405–3413.
99.
WangH., BloomO., ZhangM., VishnubhakatJ.M., OmbrellinoM., CheJ., FrazierA., YangH., IvanovaS., BorovikovaL., ManogueK.R., FaistE., AbrahamE., AnderssonJ., AnderssonU., MolinaP.E., AbumradN.N., SamaA., and TraceyK.J. (1999). HMG-1 as a later mediator of endotoxin lethality in mice. Science, 285, 248–251.
100.
YammaniR.R. (2012). S100 proteins in cartilage: role in arthritis. Biochim Biophys Acta, 1822, 600–606.
101.
YangD., TewaryP., de la RosaG., WeiF., and OppenheimJ.J. (2010). The alarmin functions of high-mobility group proteins. Biochim Biophys Acta, 1799, 157–163.
102.
YangH., LundbäckP., OttossonL., Erlandsson-HarrisH., VenereauE., BianchiM.E., Al-AbedY., AnderssonU., TraceyK.J., and AntoineD.J. (2012). Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med, 18, 250–259.
103.
YangH., and TraceyK.J. (2005). High mobility group box 1 (HMGB1). Crit Care Med, 33, S472–S474.
104.
YangH., WangH., CzuraC.J., and TraceyK.J. (2005). The cytokine activity of HMGB1. J Leukoc Biol, 78, 1–8.
105.
ZhangX., WangH., and WangJ. (2013). Expression of HMGB1 and NF-κB p65 and its significance in non-small cell lung cancer. Contemp Oncol (Pozn), 17, 350–355.
106.
ZhouP.H., LiuS.Q., and PengH. (2008). The effect of hyaluronic acid on IL-1beta-induced chondrocyte apoptosis in a rat model of osteoarthritis. J Orthop Res, 26, 1643–1648.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
